The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Pathogenesis of myeloma bone disease
Abstract
Multiple myeloma (MM) is the most common cancer to involve bone with up to 90% of patients developing bone lesions. The bone lesions are purely osteolytic in nature and do not heal in the vast majority of patients. Up to 60% of patients develop pathologic fractures over the course of their disease. Bone disease is a hallmark of MM, and myeloma bone disease differs from bone metastasis caused by other tumors. Although myeloma and other osteolytic metastases induce increased osteoclastic bone destruction, in contrast to other tumors, once myeloma tumor burden exceeds 50% in a local area, osteoblast activity is either severely depressed or absent. The basis for this severe imbalance between increased osteoclastic bone resorption and decreased bone formation has been the topic of intensive investigation over the last several years. These studies have helped to identify novel targets for treating myeloma bone disease and will be discussed in this chapter. J. Cell. Biochem. 109: 283–291, 2010. © 2009 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670 · cited 2×
“Its expression is induced by cytokines that stimulate bone resorption [Boyle et al., 2003] such as PTH, 1,25 OH Vitamin D3 and prostaglandins [Hofbauer and Heufelder, 1998; Yasuda et al., 1998].”
BackgroundOsteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
RANK is essential for osteoclast and lymph node development.
Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., et al. (1999) · Genes & Development · doi:10.1101/gad.13.18.2412 · Cited by 1,478
Li, J., Sarosi, I., Yan, X.-Q., Morony, S., Capparelli, C., Tan, H.-L., McCabe, S., Elliott, R., Scully, S., Van, G., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1566 · Cited by 1,119
RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis
Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Yano, K., Morinaga, T., & Higashio, K. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9788 · Cited by 746
Pathologic fractures correlate with reduced survival in patients with malignant bone disease
Saad, F., Lipton, A., Cook, R., Chen, Y., Smith, M., & Coleman, R. (2007) · Cancer · doi:10.1002/cncr.22991 · Cited by 667
Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche
Taichman, R. S. (2005) · Blood · doi:10.1182/blood-2004-06-2480 · Cited by 649
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.593 · Cited by 648
Franceschi, R. T., & Xiao, G. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10369 · Cited by 541
Coleman, R. E., Major, P., Lipton, A., Brown, J. E., Lee, K.-A., Smith, M., Saad, F., Zheng, M., Hei, Y. J., Seaman, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.091 · Cited by 533
Pearse, R. N., Sordillo, E. M., Yaccoby, S., Wong, B. R., Liau, D. F., Colman, N., Michaeli, J., Epstein, J., & Choi, Y. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201394498 · Cited by 518
Müller, G., Ayoub, M., Storz, P., Rennecke, J., Fabbro, D., & Pfizenmaier, K. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07188.x · Cited by 494
Body, J.-J., Facon, T., Coleman, R. E., Lipton, A., Geurs, F., Fan, M., Holloway, D., Peterson, M. C., & Bekker, P. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1933 · Cited by 490
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myeloma
Alsayed, Y., Ngo, H., Runnels, J., Leleu, X., Singha, U. K., Pitsillides, C. M., Spencer, J. A., Kimlinger, T., Ghobrial, J. M., Jia, X., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035857 · Cited by 478
Self-citationGilbert, L., He, X., Farmer, P., Rubin, J., Drissi, H., van Wijnen, A. J., Lian, J. B., Stein, G. S., & Nanes, M. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106339200 · Cited by 443
The atypical PKC-interacting protein p62 channels NF-kappa B activation by the IL-1-TRAF6 pathway
Sanz, L. (2000) · The EMBO Journal · doi:10.1093/emboj/19.7.1576 · Cited by 436
Yaccoby, S., Ling, W., Zhan, F., Walker, R., Barlogie, B., & Shaughnessy, J. D. (2007) · Blood · doi:10.1182/blood-2006-09-047712 · Cited by 433
Terpos, E., Szydlo, R., Apperley, J. F., Hatjiharissi, E., Politou, M., Meletis, J., Viniou, N., Yataganas, X., Goldman, J. M., & Rahemtulla, A. (2003) · Blood · doi:10.1182/blood-2003-02-0380 · Cited by 410
The interaction of p62 with RIP links the atypical PKCs to NF-kappa B activation
Sanz, L. (1999) · The EMBO Journal · doi:10.1093/emboj/18.11.3044 · Cited by 410
Fracture Risk With Multiple Myeloma: A Population-Based Study
Melton, L. J., Kyle, R. A., Achenbach, S. J., Oberg, A. L., & Rajkumar, S. V. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041131 · Cited by 332
Han, J.-H., Choi, S. J., Kurihara, N., Koide, M., Oba, Y., & Roodman, G. D. (2001) · Blood · doi:10.1182/blood.v97.11.3349 · Cited by 328
Self-citationSelective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro
Garrett, I. R., Chen, D., Gutierrez, G., Zhao, M., Escobedo, A., Rossini, G., Harris, S. E., Gallwitz, W., Kim, K. B., Hu, S., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16198 · Cited by 328
Giuliani, N., Colla, S., Morandi, F., Lazzaretti, M., Sala, R., Bonomini, S., Grano, M., Colucci, S., Svaldi, M., & Rizzoli, V. (2005) · Blood · doi:10.1182/blood-2004-12-4986 · Cited by 325
Abe, M., Hiura, K., Wilde, J., Shioyasono, A., Moriyama, K., Hashimoto, T., Kido, S., Oshima, T., Shibata, H., Ozaki, S., et al. (2004) · Blood · doi:10.1182/blood-2003-11-3839 · Cited by 318
Yaccoby, S., Pearse, R. N., Johnson, C. L., Barlogie, B., Choi, Y., & Epstein, J. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03257.x · Cited by 305
Toraldo, G., Roggia, C., Qian, W.-P., Pacifici, R., & Weitzmann, M. N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0136772100 · Cited by 291
Nefedova, Y., Cheng, P., Alsina, M., Dalton, W. S., & Gabrilovich, D. I. (2004) · Blood · doi:10.1182/blood-2003-07-2340 · Cited by 270
Giuliani, N., Morandi, F., Tagliaferri, S., Lazzaretti, M., Bonomini, S., Crugnola, M., Mancini, C., Martella, E., Ferrari, L., Tabilio, A., et al. (2007) · Blood · doi:10.1182/blood-2006-11-059188 · Cited by 267
Economic burden of metastatic bone disease in the U.S.
Schulman, K. L., & Kohles, J. (2007) · Cancer · doi:10.1002/cncr.22678 · Cited by 241
IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells
Lee, J. W., Chung, H. Y., Ehrlich, L. A., Jelinek, D. F., Callander, N. S., Roodman, G. D., & Choi, S. J. (2004) · Blood · doi:10.1182/blood-2003-06-1992 · Cited by 239
Self-citationTsukii, K., Shima, N., Mochizuki, S.-I., Yamaguchi, K., Kinosaki, M., Yano, K., Shibata, O., Udagawa, N., Yasuda, H., Suda, T., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8610 · Cited by 238
Choi, S. J., Oba, Y., Gazitt, Y., Alsina, M., Cruz, J., Anderson, J., & Roodman, G. D. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13116 · Cited by 231
Self-citationSanchez, P., De Carcer, G., Sandoval, I. V., Moscat, J., & Diaz-Meco, M. T. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.5.3069 · Cited by 229
Shiozawa, Y., Havens, A. M., Jung, Y., Ziegler, A. M., Pedersen, E. A., Wang, J., Wang, J., Lu, G., Roodman, G. D., Loberg, R. D., et al. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21835 · Cited by 226
Self-citationStructure and functional properties of the ubiquitin binding protein p62
Geetha, T., & Wooten, M. W. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02286-x · Cited by 223
Weitzmann, M. N., Roggia, C., Toraldo, G., Weitzmann, L., & Pacifici, R. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15687 · Cited by 223
Terpos, E., Heath, D. J., Rahemtulla, A., Zervas, K., Chantry, A., Anagnostopoulos, A., Pouli, A., Katodritou, E., Verrou, E., Vervessou, E., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06356.x · Cited by 221
Breitkreutz, I., Raab, M. S., Vallet, S., Hideshima, T., Raje, N., Mitsiades, C., Chauhan, D., Okawa, Y., Munshi, N. C., Richardson, P. G., et al. (2008) · Leukemia · doi:10.1038/leu.2008.174 · Cited by 209
IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma
Ehrlich, L. A., Chung, H. Y., Ghobrial, I., Choi, S. J., Morandi, F., Colla, S., Rizzoli, V., Roodman, G. D., & Giuliani, N. (2005) · Blood · doi:10.1182/blood-2005-03-1080 · Cited by 208
Self-citationResponse to bortezomib is associated to osteoblastic activation in patients with multiple myeloma
Zangari, M., Esseltine, D., Lee, C., Barlogie, B., Elice, F., Burns, M. J., Kang, S., Yaccoby, S., Najarian, K., Richardson, P., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05733.x · Cited by 199
Taube, T., Beneton, M. N. C., McCloskey, E. V., Rogers, S., Greaves, M., & Kanis, J. A. (1992) · European Journal of Haematology · doi:10.1111/j.1600-0609.1992.tb00046.x · Cited by 194
Osteoclasts are important for bone angiogenesis
Cackowski, F. C., Anderson, J. L., Patrene, K. D., Choksi, R. J., Shapiro, S. D., Windle, J. J., Blair, H. C., & Roodman, G. D. (2010) · Blood · doi:10.1182/blood-2009-08-237628 · Cited by 188
Self-citationThe pathogenesis of the bone disease of multiple myeloma
Edwards, C. M., Zhuang, J., & Mundy, G. R. (2008) · Bone · doi:10.1016/j.bone.2008.01.027 · Cited by 185
Thirunavukkarasu, K., Halladay, D. L., Miles, R. R., Yang, X., Galvin, R. J. S., Chandrasekhar, S., Martin, T. J., & Onyia, J. E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000322200 · Cited by 184
Wooten, M. W., Seibenhener, M. L., Mamidipudi, V., Diaz-Meco, M. T., Barker, P. A., & Moscat, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c000869200 · Cited by 180
Tanaka, Y., Abe, M., Hiasa, M., Oda, A., Amou, H., Nakano, A., Takeuchi, K., Kitazoe, K., Kido, S., Inoue, D., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2258 · Cited by 177
Terpos, E., Politou, M., Szydlo, R., Goldman, J. M., Apperley, J. F., & Rahemtulla, A. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04561.x · Cited by 167
Pathogenesis of myeloma bone disease
Roodman, G. (2004) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2004.01.001 · Cited by 163
Self-citationBortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment
Heider, U., Kaiser, M., Müller, C., Jakob, C., Zavrski, I., Schulz, C., Fleissner, C., Hecht, M., & Sezer, O. (2006) · European Journal of Haematology · doi:10.1111/j.1600-0609.2006.00692.x · Cited by 161
Minireview: Transcriptional Regulation in Development of Bone
Kobayashi, T., & Kronenberg, H. (2005) · Endocrinology · doi:10.1210/en.2004-1343 · Cited by 161
Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1
Anderson, G., Gries, M., Kurihara, N., Honjo, T., Anderson, J., Donnenberg, V. S., Donnenberg, A. D., Ghobrial, I. M., Mapara, M. Y., Stirling, D., et al. (2005) · Blood · doi:10.1182/blood-2005-08-3450 · Cited by 148
Kollet, Ó., Dar, A., & Lapidot, T. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141631 · Cited by 142
TNF-α inhibits BMP-induced osteoblast differentiation through activating SAPK/JNK signaling
Mukai, T., Otsuka, F., Otani, H., Yamashita, M., Takasugi, K., Inagaki, K., Yamamura, M., & Makino, H. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.03.099 · Cited by 138
Lu, X., Gilbert, L. C., He, X., Rubin, J. E., & Nanes, M. S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m507804200 · Cited by 138
Magrangeas, F., Nasser, V., Avet‐Loiseau, H., Loriod, B., Decaux, O., Granjeaud, S., Bertucci, F., Birnbaum, D., Nguyen, C., Harousseau, J., et al. (2003) · Blood · doi:10.1182/blood-2002-11-3385 · Cited by 129
Tumor cell dormancy: An NCI workshop report
Vessella, R. L., Pantel, K., & Mohla, S. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.9.4828 · Cited by 116
Silvestris, F., Cafforio, P., Calvani, N., & Dammacco, F. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05084.x · Cited by 105
Oyajobi, B. O., Garrett, I. R., Gupta, A., Flores, A., Esparza, J. M., Munoz, S. A., Zhao, M., & Mundy, G. R. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06829.x · Cited by 102
Vij, R., Horvath, N., Spencer, A. G., Taylor, K., Vadhan‐Raj, S., Vescio, R. A., Smith, J. W. G., Qian, Y., Yeh, H., & Jun, S. (2009) · American Journal of Hematology · doi:10.1002/ajh.21509 · Cited by 99
Development of an in vivo model of human multiple myeloma bone disease
Alsina, M., Boyce, B. F., Devlin, R. D., Anderson, J. L., Craig, F. E., Mundy, G. R., & Roodman, G. D. (1996) · Blood · doi:10.1182/blood.v87.4.1495.bloodjournal8741495 · Cited by 97
Self-citationHashimoto, T., Abe, M., Oshima, T., Shibata, H., Ozaki, S., Inoue, D., & Matsumoto, T. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04864.x · Cited by 89
Fluid Shear Stress Inhibits TNFα-induced Osteocyte Apoptosis
Tan, S., Kuijpers‐Jagtman, A. M., Semeins, C. M., Bronckers, A. L. J. J., Maltha, J. C., den Hoff, J. W. V., Everts, V. E., & Klein‐Nulend, J. (2006) · Journal of Dental Research · doi:10.1177/154405910608501006 · Cited by 86
Evolving concepts on the microenvironmental niche for hematopoietic stem cells
Raaijmakers, M. H. G. P., & Scadden, D. T. (2008) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328303e14c · Cited by 83
MIP-1α (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma
Masih‐Khan, E., Trudel, S., Heise, C. C., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017087 · Cited by 80
Lee, S., Kalinowski, J., Jacquin, C., Adams, D. J., Gronowicz, G., & Lorenzo, J. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060117 · Cited by 78
Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis
Hofbauer, L. C., & Heufelder, A. E. (1998) · European Journal of Endocrinology · doi:10.1530/eje.0.1390152 · Cited by 74
Diamond, T., Levy, S., Day, P. J., Barbagallo, S., Manoharan, A., & Kwan, Y. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.1042920.x · Cited by 73
Role of stromal-derived cytokines and growth factors in bone metastasis
Roodman, G. D. (2003) · Cancer · doi:10.1002/cncr.11148 · Cited by 71
Self-citationHjorth-Hansen, H., Seifert, M. F., Börset, M., Aarset, H., Östlie, A., Sundan, A., & Waage, A. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.2.256 · Cited by 71
Li, B.-Z., Shi, M., Li, J., Zhang, H., Chen, B., Chen, L., Gao, W., Giuliani, N., & Zhao, R. C. (2007) · Stem Cells and Development · doi:10.1089/scd.2007.0074 · Cited by 68
Nguyen, A. N., Stebbins, E. G., Henson, M., O’Young, G., Choi, S. J., Quon, D. H., Damm, D., Reddy, M., Ma, J. Y., Haghnazari, E., et al. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.02.026 · Cited by 67
Self-citationNimmanapalli, R., Gerbino, E., Dalton, W. S., Gandhi, V. V., & Alsina, M. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07217.x · Cited by 62
Hiruma, Y., Honjo, T., Jelinek, D. F., Windle, J. J., Shin, J., Roodman, G. D., & Kurihara, N. (2009) · Blood · doi:10.1182/blood-2008-08-173948 · Cited by 60
Self-citationNew Insights in Myeloma-induced Osteolysis
Barillé‐Nion, S., & Bataille, R. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819031000082966 · Cited by 59
Treatment strategies for bone disease
Roodman, G. D. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705802 · Cited by 42
Self-citationLee, Y. H., Ko, J., Joung, I., Kim, J.-H., & Shin, J. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01323-4 · Cited by 34
Proteasome inhibition in multiple myeloma
Kropff, M. H., Bisping, G., Wenning, D., Berdel, W. E., & Kienast, J. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.02.015 · Cited by 25
Vanderkerken, K., Medicherla, S., Coulton, L. A., Camp, B. V., Protter, A., Higgins, L. S., Menu, E., & Croucher, P. I. (2006) · Blood · doi:10.1182/blood.v108.11.3436.3436 · Cited by 7
Cited by
Role and mechanism of action of sclerostin in bone
Delgado-Calle, J., Sato, A. Y., & Bellido, T. (2017) · Bone · doi:10.1016/j.bone.2016.10.007 · Cited by 443
Bone metastasis: mechanisms and therapeutic opportunities
Suva, L. J., Washam, C., Nicholas, R. W., & Griffin, R. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.227 · Cited by 424
Bone Marrow Microenvironment in Multiple Myeloma Progression
Manier, S., Sacco, A., Leleu, X., Ghobrial, I. M., & Roccaro, A. M. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/157496 · Cited by 301
Hypercalcemia of malignancy: An update on pathogenesis and management
Mirrakhimov, A. (2015) · North American Journal of Medical Sciences · doi:10.4103/1947-2714.170600 · Cited by 290
Pathogenesis beyond the cancer clone(s) in multiple myeloma
Bianchi, G., & Munshi, N. C. (2015) · Blood · doi:10.1182/blood-2014-11-568881 · Cited by 288
Metadata
- Authors
- Roodman, G. D.
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 2009-12-11
- Volume
- 109
- Issue
- 2
- Pages
- 283-291
- ISSN
- 0730-2312 (ISSN-L)
- 1097-4644
- OpenAlex
- W2106309343
- Cited by
- 296
- References
- 83
- FWCI
- 12.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.